Laurent Peyrin-Biroulet spends much of his time researching Internal medicine, Crohn's disease, Ulcerative colitis, Inflammatory bowel disease and Surgery. His research combines Gastroenterology and Internal medicine. His Crohn's disease study results in a more complete grasp of Disease.
His Ulcerative colitis course of study focuses on Colitis and Drug resistance. His research in Inflammatory bowel disease focuses on subjects like Immunology, which are connected to Single-nucleotide polymorphism. His Surgery research includes themes of Adverse effect, Incidence and Cohort study.
His primary areas of study are Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology. In general Internal medicine study, his work on Disease, Infliximab, Adalimumab and Vedolizumab often relates to the realm of In patient, thereby connecting several areas of interest. His Inflammatory bowel disease research incorporates elements of Odds ratio, Retrospective cohort study, Immunology and Intensive care medicine.
His Ulcerative colitis research integrates issues from Adverse effect, Clinical trial, Colitis and Ustekinumab. His research in Crohn's disease intersects with topics in Surgery, Cohort study, MEDLINE, Pediatrics and Cohort. While the research belongs to areas of Gastroenterology, Laurent Peyrin-Biroulet spends his time largely on the problem of Placebo, intersecting his research to questions surrounding Randomized controlled trial.
Laurent Peyrin-Biroulet mostly deals with Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology. His work on Vedolizumab, Ustekinumab, Infliximab and Adverse effect is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science. His Inflammatory bowel disease research is multidisciplinary, relying on both Pandemic, Coronavirus disease 2019, MEDLINE and Intensive care medicine.
His studies deal with areas such as Tofacitinib, Colitis and Clinical trial, Randomization as well as Ulcerative colitis. Crohn's disease is a subfield of Disease that he investigates. His Gastroenterology study incorporates themes from Inflammation, Faecal calprotectin, Placebo, Biopsy and Endoscopy.
His primary scientific interests are in Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology. His Inflammatory bowel disease research incorporates themes from Pandemic, Coronavirus disease 2019, Intensive care medicine and Outbreak. His study looks at the relationship between Ulcerative colitis and fields such as Psoriasis, as well as how they intersect with chemical problems.
Disease covers Laurent Peyrin-Biroulet research in Crohn's disease. When carried out as part of a general Disease research project, his work on Disease burden is frequently linked to work in Clinical Practice, therefore connecting diverse disciplines of study. His Gastroenterology research integrates issues from Biomarker, Faecal calprotectin, Clinical trial and Biopsy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
Carl A. Anderson;Gabrielle Boucher;Charlie W. Lees;Andre Franke.
Nature Genetics (2011)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollón;Axel Dignass;Vito Annese;Herbert Tilg.
Journal of Crohns & Colitis (2017)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch.
The American Journal of Gastroenterology (2015)
Joana Torres;Saurabh Mehandru;Jean-Frédéric Colombel;Laurent Peyrin-Biroulet.
The Lancet (2017)
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
Laurent Peyrin-Biroulet;Edward V. Loftus;Jean Frederic Colombel;William J. Sandborn.
The American Journal of Gastroenterology (2010)
Iron deficiency anaemia
Anthony Lopez;Patrice Cacoub;Iain C Macdougall;Laurent Peyrin-Biroulet.
The Lancet (2016)
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
J. Panes;Y. Bouhnik;W. Reinisch;J. Stoker.
Journal of Crohn's and Colitis (2013)
Development of the Crohn's disease digestive damage score, the Lémann score†‡§
Benjamin Pariente;Jacques Cosnes;Silvio Danese;William J. Sandborn.
Inflammatory Bowel Diseases (2011)
Clinical implications of mucosal healing for the management of IBD
Guillaume Pineton de Chambrun;Laurent Peyrin-Biroulet;Marc Lémann;Jean-Frédéric Colombel.
Nature Reviews Gastroenterology & Hepatology (2010)
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Laurent Peyrin-Biroulet;Walter Reinisch;Jean-Frederic Colombel;Gerassimos J Mantzaris.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: